A study claims that artificial intelligence could speed up the diagnosis and treatment of gliomas by making it possible to check for genetic alterations in dangerous brain tumors in less than 90 seconds. DeepGlioma is an AI-based diagnostic screening system that employs fast imaging to examine tumor specimens obtained during an operation and find genetic abnormalities more quickly.
Before DeepGlioma, there was no way for doctors to tell diffuse gliomas apart during surgery. The technology, developed in 2019, combines deep neural networks with the stimulated Raman histology optical imaging technique to examine brain tumor tissue in real-time.
With the help of DeepGlioma, healthcare professionals will have a greater opportunity to design treatments and project patient prognoses. Patients with diffuse glioma have few therapeutic choices, even while receiving the best quality of care. Malignant diffuse glioma patients had an 18-month median survival period.
The recently created diagnostic screening method successfully identified mutations used by the WHO to establish molecular subgroups of the illness in a study of more than 150 individuals with diffuse glioma, the most prevalent and lethal primary brain tumor. The average accuracy was over 90%. According to the author, this AI-based technology could enhance patient access to diagnosis and treatment for patients with fatal brain tumors.
Related Content: Lung Tumors – Sensors Could Offer Early Detection